Aimmune Therapeutics, Inc. (NasdaqGS:AIMT) announced that it has entered into a loan agreement with an affiliate of KKR & Co. Inc. (NYSE:KKR) for gross proceeds of $170 million on January 4, 2019. The loan can be prepaid at Aimmune's discretion, at any time, subject to prepayment fees. The transaction will take place in three tranches. On the same date, the company announced that it has received $40 million in its first tranche of the transaction. Remaining $85 million will be raised upon the Food and Drug Administration's approval of AR101 and satisfaction of other customary borrowing conditions and $45 million at the company's option in 2020 upon the satisfaction of certain borrowing conditions.